Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866483 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL12148896 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL12087758 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL16552975 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL12667224 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL16553079 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL12667229 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL16553206 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL13561439 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL24073302 | 0.92 | LPAR3 (0.64) | EPHX2LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2496260-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | Marina Biotech, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057020-A1 | ACTIVITY GENERATING DELIVERY MOLECULES | MARINA BIOTECH, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073038-A1 | DELIVERY MOLECULES FOR THERAPEUTICS | LNPEP, LDLR, XPA | SLC6A5 2329/4885EPHX2 2878/4885LPAR3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.